EGFR and non-small cell lung carcinoma: These observations with the CDX models showed that initial EGFR inhibition significantly delayed the regrowth of ALK-rearranged NSCLC tumors with both rapid and slow recurrences after lorlatinib treatment by accelerating cell apoptosis.